The company's focus is on innate immunity and the modulation of the TLR3 receptor, with the goal of developing TL-532, a cancer immunotherapy that uses a synthetically produced double-stranded RNA specific to the TLR3 receptor. This approach aims to provide good tolerance and auto vaccination against cancer recurrences for patients with various types of cancer.